Broadcast series with ACCOMPANYING Tweetorials

Ushering in a New Era in the Treatment of Chronic Kidney Disease and Anemia: Appreciating The Patient Burden, Exploring Pathways and Pathogenesis, Reflecting on the New and Emerging Data

Overview
Learning Objectives
Faculty and Disclosures

Program Overview

Relatively recent advancements in the understanding of the pathophysiology of CKD-associated anemia has led to the discovery of viable treatment targets, yet nephrologists may lack awareness of these therapeutic developments. Additionally, certain healthcare disparities may limit comprehensive management across the broader population of patients with anemia and CKD, consequently increasing the global burden of this complication. To ensure appropriate care and outcomes for patients, nephrologists require up-to-date education on the pathophysiology of anemia and CKD, burden of disease, current and emerging treatment options, and barriers to care.

Target Audience

This educational activity has been designed for US-based nephrology healthcare professionals (HCPs), including nephrology physicians, physician assistants (PAs), nurse practitioners (NPs), and residents.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Summarize the prevalence and burden associated with anemia in patients with CKD
  • Describe the rationale of targeting the PHI/HIF for the treatment of anemia in CKD
  • Cite the efficacy and safety data of novel agents used to manage anemia in CKD
  • Recognize disparities in the management of anemia in CKD

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Ajay K. Singh MBBS, FRCP (UK), MBA (Chair)
Senior Associate Dean for Postgraduate Medical Education Director, Master in Medical Sciences in Clinical Investigation (MMSCI) Program Harvard Medical School Cambridge, Massachusetts
Disclosures:
Consulting Fee (e.g., Advisory Board): Bayer, GlaxoSmithKline, Zydus
Edgar V. Lerma, MD
Clinical Professor of Medicine
University of Illinois at Chicago
Chicago, Illinois
Disclosures:
Consulting Fee (e.g., Advisory Board): Akebia, AstraZeneca, Bayer, GlaxoSmithKline, Otsuka, Vifor
Honoraria: Akebia, AstraZeneca, Bayer, GlaxoSmithKline, Otsuka, Vifor
Speakers’ Bureau: Bayer, GlaxoSmithKline, Otsuka, Vifor
Jay B. Wish, MD
Professor of Clinical Medicine
Indiana University School of Medicine
Chief Medical Officer for Outpatient Dialysis
Indiana University Health
Indianapolis, Indiana
Disclosures:
Consulting Fee (e.g., Advisory Board): Akebia, Amgen, AstraZeneca, CSL Behring, Disc Medicine, Fibrogen, GlaxoSmithKline, Otuska, Rockwell Medical, Vifor
Honoraria: Akebia, Amgen, AstraZeneca, CSL Behring, Disc Medicine, Fibrogen, GlaxomithKline, Otuska, Rockwell Medical, Vifor
Speakers’ Bureau: Akebia, AstraZeneca
This educational activity was supported by an independent educational grant from GSK.

Learning program contents